EWOLUTION: Design of a registry to evaluate real-world clinical outcomes in patients with AF and high stroke risk-treated with the WATCHMAN left atrial appendage closure technology

Background Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and the rate of ischemic stroke attributed to non‐valvular AF is estimated at 5% per year. Several multi‐center studies established left atrial appendage closure as a safe and effective alternative to oral anticoagul...

Full description

Saved in:
Bibliographic Details
Published in:Catheterization and cardiovascular interventions 2016-09, Vol.88 (3), p.460-465
Main Authors: Boersma, Lucas V.A., Schmidt, Boris, Betts, Tim R., Sievert, Horst, Tamburino, Corrado, Teiger, Emmanuel, Stein, Kenneth M., Bergmann, Martin W.
Format: Article
Language:English
Subjects:
Atrial Appendage - diagnostic imaging
Atrial Appendage - physiopathology
Atrial Fibrillation - complications
Atrial Fibrillation - diagnosis
Atrial Fibrillation - physiopathology
Atrial Fibrillation - therapy
Cardiac Catheterization - adverse effects
Cardiac Catheterization - instrumentation
Cardiac Catheterization - methods
cardiac embolus
cerebrovascular accident
Europe
Humans
Middle East
prevention
Product Surveillance, Postmarketing
Prospective Studies
Registries
Research Design
Risk Assessment
Risk Factors
Stroke - diagnosis
Stroke - etiology
Stroke - prevention & control
Time Factors
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia and the rate of ischemic stroke attributed to non‐valvular AF is estimated at 5% per year. Several multi‐center studies established left atrial appendage closure as a safe and effective alternative to oral anticoagulation, but there is a need for additional real world data. Methods The purpose of this observational, prospective, single‐arm, multicenter clinical study is to compile real‐world clinical outcome data for WATCHMAN™ LAA (left atrial appendage) Closure Technology. One thousand subjects at up to 70 institutions in Europe, the Middle East, and Russia will be enrolled. Patients will be followed for 2 years after WATCHMAN implantation, according to standard medical practice. Primary endpoints include procedural and long‐term data including stroke/embolism, bleeding, and death. This article presents the background of the LAAC device and describes the design of the study. Results Results for peri‐procedural analyses are expected toward the end of 2015; long‐term follow‐up data are expected in the latter half of 2017. Conclusion The EWOLUTION study will formally expand knowledge of LAA closure into a broader real world setting. © 2015 Wiley Periodicals, Inc.
ISSN:1522-1946
1522-726X
DOI:10.1002/ccd.26358